BNP Paribas Upgrades Amentum Holdings to Neutral, Lowers Price Target to $20
BNP Paribas analyst Matthew Akers upgrades Amentum Holdings (NYSE:AMTM) from Underperform to Neutral and lowers the price target from $21 to $20.
Stocks · News reference
Wall Street analysts change outlook on top names. HC Wainwright raises price target for Belite Bio, while B of A cuts Lumentum's target.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
BNP Paribas analyst Matthew Akers upgrades Amentum Holdings (NYSE:AMTM) from Underperform to Neutral and lowers the price target from $21 to $20.
Filed: 2026-10-02 AccNo: 0002011286-26-000026 Size: 5 MB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Needham analyst Bernie McTernan reiterates AppLovin (NASDAQ:APP) with a Buy and maintains $475 price target.
The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQQ has beaten equal-weight QQQE by 8% since late July.
Unity Software shares are rising Monday. Piper Sandler reiterated its rating and price target ahead of the company's third-quarter report.